Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12541 | 0.89 | — | — | |
| SCHEMBL28061440 | 0.89 | CA1 (0.63) | NFE2L2L3MBTL1KCNH2CA12CA1 | |
| SCHEMBL29635862 | 0.89 | — | — | |
| Water SCHEMBL28959107 | 0.86 | CA1 (0.60) | NFE2L2L3MBTL1KCNH2CA12CA1 | |
| SCHEMBL2973304 | 0.86 | CA1 (0.60) | NFE2L2L3MBTL1KCNH2CA12CA1 | |
| SCHEMBL3907382 | 0.86 | CA1 (0.60) | NFE2L2L3MBTL1KCNH2CA12CA1 | |
| SCHEMBL972033 | 0.86 | CA1 (0.60) | NFE2L2L3MBTL1KCNH2CA12CA1 | |
| Ammonia Solution, Strong SCHEMBL4261840 | 0.86 | CA1 (0.60) | NFE2L2L3MBTL1KCNH2CA12CA1 | |
| Phosphine SCHEMBL17580357 | 0.86 | CA1 (0.60) | NFE2L2L3MBTL1KCNH2CA12CA1 | |
| Hydrogen Sulfide SCHEMBL28185953 | 0.86 | CA1 (0.60) | NFE2L2L3MBTL1KCNH2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110256305-A | A kind of naphthalenesulfonamide compound, preparation method and application | 中国药科大学 | 2019-09-20 | — | — | CN | disclosed |
| CN-109311894-A | N- (substituted-phenyl) -sulfonamide derivatives as kinase inhibitors | 内尔维阿诺医学科学有限公司 | 2019-02-05 | — | — | CN | disclosed |
| CN-102036967-B | As 5-HT6Arylsulfonyl pyrazoline carboxamidine derivatives as antagonists | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2014-10-15 | — | — | CN | disclosed |
| CN-104003937-A | Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists | ABBOTT HEALTHCARE PRODUCTS BV | 2014-08-27 | — | — | CN | disclosed |
| CN-102875441-A | Plexxikon inc | PLEXXIKON INC | 2013-01-16 | — | — | CN | disclosed |
| US-20090221711-A1 | TRIFLUOROMETHYL-CONTAINING PHENYLSULFONAMIDE BETA AMYLOID INHIBITORS | WYETH (US) | 2009-09-03 | — | — | US | disclosed |
| US-7550629-B2 | 4-chloro-N-[(1S)-3,3,3-trifluoro-1-(hydroxymethyl)-2-(trifluoromethyl)propyl]benzenesulfonamide; 4-cyano-N-(3,3,3-trifluoro-1-hydroxymethyl-2-trifluoromethyl-propyl)-benzenesulfonamide; Alzheimer's Disease, amyloid angiopathy, systemic amyloidosis, mild cognitive impairment and Down's syndrome | WYETH (US) | 2009-06-23 | — | — | US | disclosed |
| US-20070249722-A1 | Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors | WYETH (US) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221711-A1 | TRIFLUOROMETHYL-CONTAINING PHENYLSULFONAMIDE BETA AMYLOID INHIBITORS | APP, PSEN1, BACE1 | NFE2L2 3659/4885L3MBTL1 995/4885KCNH2 3528/4885 |
| US-20070249722-A1 | Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors | APP, PSEN1, BACE1 | NFE2L2 3659/4885L3MBTL1 995/4885KCNH2 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.